Jason Haas bought $161k of SYRS
Chief Financial Officer at Syros Pharmaceuticals, Inc.. 100,000 shares at an average of $1.61, traded Sep 10, 2024, filed Sep 12, 2024.
Score components
- +22RoleCFO
- +11Trade size$161k at market
- +10Relative to holdingsHoldings up 407%
- +18Price context4% above the 52-week low; 80% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +22.9%, 3m -85.0%, 6m -95.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-105995, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 10, 2024 | POpen-market purchase Common Stock | +35,363 | $1.55 | $55k | 59,915 | Sep 12, 2024 |
| Sep 11, 2024 | POpen-market purchase Common Stock | +19,293 | $1.58 | $30k | 79,208 | Sep 12, 2024 |
| Sep 12, 2024 | POpen-market purchase Common Stock | +45,344 | $1.68 | $76k | 124,552 | Sep 12, 2024 |
Related signals
Other insiders at Syros Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Syros Pharmaceuticals, Inc. | Nancy A Simonian President & CEO | $10k 37,070 shares | -90% | |
| 56Moderate | Syros Pharmaceuticals, Inc. | Nancy A Simonian President & CEO | $36k 134,713 shares | -77% | |
| 65Notable | Syros Pharmaceuticals, Inc. | Conley Chee President & CEO | $27k 134,797 shares | -100% | |
| 62Notable | Syros Pharmaceuticals, Inc. | Jason Haas Chief Financial Officer | $29k 137,803 shares | -100% | |
| 50Moderate | Syros Pharmaceuticals, Inc. | Gerald E Quirk Chief Legal & Compliance Offic | $10k 46,657 shares | -100% | |
| 50Moderate | Syros Pharmaceuticals, Inc. | David Roth Chief Medical Officer | $2,382 12,099 shares | -100% | |
| 50Moderate | Syros Pharmaceuticals, Inc. | Kristin Stephens Chief Development Officer | $7,949 36,133 shares | -100% | |
| 72Notable | Syros Pharmaceuticals, Inc. | Conley Chee President & CEO | $161k 100,000 shares | +444% | |
| 27Weak | Syros Pharmaceuticals, Inc. | Richard A Young director | $178k 34,837 shares | -81% | |
| 22Weak | Syros Pharmaceuticals, Inc. | David Roth Chief Medical Officer | $52k 10,451 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.